why choose us

First received: August 08, 2024

Clinical Trial: A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Multiple Myeloma

Study Type: OBSERVATIONAL


Official Title: Comparative Effectiveness of Elranatamab in Clinical Study C1071003 Versus Physician's Choice of Treatment (PCT) in Real-World (RW) External Control Arms in Patients With Triple-Class Refractory

Brief Summary: This study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM).Sometimes MM might improve at first, but then gets resistant to the treatment and starts growing again (known as relapsed refractory).This study medicine will be compared with standard-of-care (SOC) therapies used in real-world clinical practice.For people receiving elranatamab, the investigators will use data from the phase 2 clinical trial (MagnetisMM-3).The investigators will also use data…

Read more